Allium Group Receives CE Mark For Its Next-Generation Prostatic Stent

Allium Group, the developer and manufacturer of innovative stents for the urinary, gastro-intestinal, pulmonary and peripheral vascular tracts, announced today that it has been awarded CE mark for its prostatic stent enabling commercialization of the system in the European Union and the countries that recognize the CE Mark. “We are excited about receiving the European CE approval for our Prostatic stent.

More: continued here

Filed under: Urology on January 16th, 2009